FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2397153732> ?p ?o ?g. }

• W2397153732 endingPage "197" @default.
• W2397153732 startingPage "161" @default.
• W2397153732 abstract "In “hypethermia”, the procedure of raising the temperature of a part, or the whole body, up to 42° C to kill cancer cells for a defined period of time is applied alone or as an adjunctive with various established cancer treatment modalities such as radiotherapy and chemotherapy. However, hyperthermia is not generally accepted as conventional therapy due to the complications of deep heating and lack of focusing of the heat effect only for malignant tissues. The idea of oncothermia solves the selective deep action on malignant tissue on nearly cellular level. Oncothermia is highly improved, safe and effective “hyperthermia“ in clinical cancer therapy supported by in vivo, in vitro, and human research as shown in this article. Advantage of oncothermia : while the classical insufficiently, focused hyperthermia has to heat up in case of the multiple lesions overlapping all the volume, which contains both normal tissues and malignant tissues; while oncothermia automatically focuses on the malignant tissues in its multiple places, without treating the healthy tissue in between. The modulated radiofrequency current (RF) flows through the malignancies only. The radiofrequency modulated current with 13,56 MHz (fractal modulated) between 2 electrodes automatically focuses through malignant tissues with lower impedance and will flow mainly in the extracellular electrolyte because the normal cells are electronically isolated by their membrane by more than one-million V/m electrical field strength. Oncothermia body, up to 42° C to kill cancer cells for a defined period of time is applied alone or as an adjunctive with various established cancer treatment modalities such as radiotherapy and chemotherapy. However, hyperthermia is not generally accepted as conventional therapy due to the complications of deep heating and lack of focusing of the heat effect only for malignant tissues. The idea of oncothermia solves the selective deep action on malignant tissue on nearly cellular level. Oncothermia is highly improved, safe and effective “hyperthermia” in clinical cancer therapy supported by in vivo, in vitro, and human research as shown in this article. Advantage of oncothermia : while the classical insufficiently, focused hyperthermia has to heat up in case of the multiple lesions overlapping all the volume, which contains both normal tissues and malignant tissues; while oncothermia automatically focuses on the malignant tissues in its multiple places, without treating the healthy tissue in between. The modulated radiofrequency current (RF) flows through the malignancies only. The radiofrequency modulated current with 13,56 MHz (fractal modulated) between 2 electrodes automatically focuses through malignant tissues with lower impedance and will flow mainly in the extracellular electrolyte because the normal cells are electronically isolated by their membrane by more than one-million V/m electrical field strength. Oncothermia today has the ability to be a candidate to a widely accepted modality of the standard cancer treatment." @default.
• W2397153732 created "2016-06-24" @default.
• W2397153732 creator A5041853151 @default.
• W2397153732 creator A5069679403 @default.
• W2397153732 creator A5077644429 @default.
• W2397153732 date "2013-12-03" @default.
• W2397153732 modified "2023-09-23" @default.
• W2397153732 title "A New Paradigm and Promising Method in Cancer Therapies Oncothermia: a New Paradigm and Promising Method in Cancer Therapies" @default.
• W2397153732 cites W185222188 @default.
• W2397153732 cites W1982164780 @default.
• W2397153732 cites W1984885117 @default.
• W2397153732 cites W1985884345 @default.
• W2397153732 cites W1995207520 @default.
• W2397153732 cites W1997388889 @default.
• W2397153732 cites W2000375804 @default.
• W2397153732 cites W2000831227 @default.
• W2397153732 cites W2006616651 @default.
• W2397153732 cites W2008879046 @default.
• W2397153732 cites W2010368710 @default.
• W2397153732 cites W2014092937 @default.
• W2397153732 cites W2016602764 @default.
• W2397153732 cites W2025170599 @default.
• W2397153732 cites W2028248095 @default.
• W2397153732 cites W2037603547 @default.
• W2397153732 cites W2039295792 @default.
• W2397153732 cites W2052787194 @default.
• W2397153732 cites W2054580421 @default.
• W2397153732 cites W2073511676 @default.
• W2397153732 cites W2073904936 @default.
• W2397153732 cites W2077997624 @default.
• W2397153732 cites W2081371019 @default.
• W2397153732 cites W2085659983 @default.
• W2397153732 cites W2087287133 @default.
• W2397153732 cites W2090845915 @default.
• W2397153732 cites W2092618667 @default.
• W2397153732 cites W2101043797 @default.
• W2397153732 cites W2108151807 @default.
• W2397153732 cites W2112126723 @default.
• W2397153732 cites W2118661742 @default.
• W2397153732 cites W2123911739 @default.
• W2397153732 cites W2127427539 @default.
• W2397153732 cites W2131391680 @default.
• W2397153732 cites W2152903693 @default.
• W2397153732 cites W2408831326 @default.
• W2397153732 cites W2413887531 @default.
• W2397153732 cites W4237067690 @default.
• W2397153732 cites W4361745535 @default.
• W2397153732 doi "https://doi.org/10.3727/036012913x13831832269243" @default.
• W2397153732 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24494322" @default.
• W2397153732 hasPublicationYear "2013" @default.
• W2397153732 type Work @default.
• W2397153732 sameAs 2397153732 @default.
• W2397153732 citedByCount "12" @default.
• W2397153732 countsByYear W23971537322014 @default.
• W2397153732 countsByYear W23971537322016 @default.
• W2397153732 countsByYear W23971537322018 @default.
• W2397153732 countsByYear W23971537322019 @default.
• W2397153732 countsByYear W23971537322020 @default.
• W2397153732 countsByYear W23971537322021 @default.
• W2397153732 countsByYear W23971537322022 @default.
• W2397153732 countsByYear W23971537322023 @default.
• W2397153732 crossrefType "journal-article" @default.
• W2397153732 hasAuthorship W2397153732A5041853151 @default.
• W2397153732 hasAuthorship W2397153732A5069679403 @default.
• W2397153732 hasAuthorship W2397153732A5077644429 @default.
• W2397153732 hasConcept C121608353 @default.
• W2397153732 hasConcept C126322002 @default.
• W2397153732 hasConcept C142724271 @default.
• W2397153732 hasConcept C143998085 @default.
• W2397153732 hasConcept C150903083 @default.
• W2397153732 hasConcept C207001950 @default.
• W2397153732 hasConcept C2776694085 @default.
• W2397153732 hasConcept C2779949491 @default.
• W2397153732 hasConcept C3019816032 @default.
• W2397153732 hasConcept C502942594 @default.
• W2397153732 hasConcept C509974204 @default.
• W2397153732 hasConcept C71924100 @default.
• W2397153732 hasConcept C86803240 @default.
• W2397153732 hasConcept C96232424 @default.
• W2397153732 hasConceptScore W2397153732C121608353 @default.
• W2397153732 hasConceptScore W2397153732C126322002 @default.
• W2397153732 hasConceptScore W2397153732C142724271 @default.
• W2397153732 hasConceptScore W2397153732C143998085 @default.
• W2397153732 hasConceptScore W2397153732C150903083 @default.
• W2397153732 hasConceptScore W2397153732C207001950 @default.
• W2397153732 hasConceptScore W2397153732C2776694085 @default.
• W2397153732 hasConceptScore W2397153732C2779949491 @default.
• W2397153732 hasConceptScore W2397153732C3019816032 @default.
• W2397153732 hasConceptScore W2397153732C502942594 @default.
• W2397153732 hasConceptScore W2397153732C509974204 @default.
• W2397153732 hasConceptScore W2397153732C71924100 @default.
• W2397153732 hasConceptScore W2397153732C86803240 @default.
• W2397153732 hasConceptScore W2397153732C96232424 @default.
• W2397153732 hasIssue "3" @default.
• W2397153732 hasLocation W23971537321 @default.
• W2397153732 hasLocation W23971537322 @default.
• W2397153732 hasOpenAccess W2397153732 @default.
• W2397153732 hasPrimaryLocation W23971537321 @default.

• next